KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Inventory (2016 - 2026)

AbbVie has reported Inventory over the past 14 years, most recently at $5.0 billion for Q4 2025.

  • Quarterly Inventory rose 18.42% to $5.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 billion through Dec 2025, up 18.42% year-over-year, with the annual reading at $5.0 billion for FY2025, 18.42% up from the prior year.
  • Inventory was $5.0 billion for Q4 2025 at AbbVie, roughly flat from $4.9 billion in the prior quarter.
  • Over five years, Inventory peaked at $5.0 billion in Q2 2025 and troughed at $3.1 billion in Q3 2021.
  • The 5-year median for Inventory is $4.0 billion (2023), against an average of $3.9 billion.
  • The largest YoY upside for Inventory was 77.44% in 2021 against a maximum downside of 16.58% in 2021.
  • A 5-year view of Inventory shows it stood at $3.1 billion in 2021, then grew by 14.42% to $3.6 billion in 2022, then increased by 14.53% to $4.1 billion in 2023, then grew by 2.0% to $4.2 billion in 2024, then grew by 18.42% to $5.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Inventory are $5.0 billion (Q4 2025), $4.9 billion (Q3 2025), and $5.0 billion (Q2 2025).